Expanding into MEA is a high-stakes decision involving capital, credibility, partners, and long-term responsibility. I work with MedTech CEOs, founders, and international business leaders to build defensible commercial plans and execute them with discipline on the ground.
Most MedTech companies don’t struggle in MEA because their technology is weak. They struggle because assumptions travel faster than understanding: across fragmented markets, shifting regulations, and relationship-driven commercial pathways.
Leaders preparing for MEA expansion decisions and accountable for commercial outcomes.
Teams responsible for commercialization, distribution, or market access across MEA.
Organizations navigating partner selection, regulatory readiness, and commercial execution across MEA.
Leaders who value clarity, integrity, and long-term impact over speed.
Middle East and Africa, with a primary focus on Gulf markets, especially Saudi Arabia and the UAE, approached with regional nuance, cultural context, and long-term partnership discipline.
Many companies enter MEA without decision clarity.
Country dynamics, decision pathways, and incentives vary widely. It deserve deliberate prioritization.
Distribution isn’t logistics. It’s a long-term partnership that requires diligence in selection and discipline in activation.
MEA rewards patience, context, and credibility.
Five execution-led commercial workstreams that turn MEA intent into disciplined market entry and scale.
Focus the MEA map: where to play, where not to, and why.
Avoid diluted effort and expensive misfires.
Confirm regulatory pathways, requirements, and sequencing by country.
Remove readiness blind spots before committing resources.
Select partners based on capability and incentives, not promises.
Structure for activation, not just signing.
Translate strategy into early adoption: KOL motion, pilots, and first revenue paths.
Execute with real feedback loops from the field.
Align stakeholders and run a clear performance cadence with partners.
Scale what works. Stop what doesn’t.
We exist to bridge the gap between medical innovation and patient impact. Every technology we help launch represents improved outcomes, enhanced quality of life, and lives saved across the Middle East and Africa region.
MedTech Commercial Strategy & Execution (MEA) · Innovation Advisory
I grew up in a Syrian family where integrity, discipline, and honesty were not abstract values—they were standards we lived by. That grounding shapes how I approach partnerships and long-term value creation in healthcare.
"Ambition is real. But it means nothing without integrity, clarity, and people who show up when it counts."
Over 15+ years, I have lived, studied, and worked across Syria, Saudi Arabia, Egypt, Turkey, Canada, the United States, and the UAE. My work sits at the intersection of business development, go-to-market strategy, and market access for MedTech companies entering or scaling in Middle East and Africa markets.
Successful commercialization across Dentistry, Dermatology, Ophthalmology, Gastroenterology, Orthopaedics, Urology, Neurology, and Spine—from simple mechanical devices to sophisticated image-guided surgical navigation systems.
Based in Dubai, UAE · Syrian-Canadian with roots in Saudi Arabia
If MEA expansion is on your roadmap, or under discussion internally, the right starting point is not activity. It’s clarity around markets, partners, readiness, and execution pathways.
Scan for WhatsApp
+971 56 223 9603